Mesoblast (NASDAQ:MESO) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Mesoblast (NASDAQ:MESO) to a strong-buy rating in a research note released on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast’s FY2025 earnings at ($0.70) EPS.

Several other analysts have also issued reports on MESO. Piper Sandler restated an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Trading Down 7.7 %

Shares of MESO stock opened at $13.68 on Tuesday. The company’s 50-day moving average price is $17.94 and its 200-day moving average price is $12.33. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a twelve month low of $2.05 and a twelve month high of $22.00.

Institutional Trading of Mesoblast

Institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd purchased a new stake in Mesoblast during the fourth quarter worth about $30,000. Barclays PLC purchased a new stake in Mesoblast during the fourth quarter worth about $38,000. Lindbrook Capital LLC increased its stake in Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after purchasing an additional 901 shares during the period. JPMorgan Chase & Co. purchased a new stake in Mesoblast during the fourth quarter worth about $50,000. Finally, BNP Paribas Financial Markets increased its stake in Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock worth $51,000 after purchasing an additional 2,597 shares during the period. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.